GlassScriptPhysician profile
Kristen Abbott
NPI 1700597382
$2,817.12
in general payments reported to CMS, 2019-2025
28 companies · $1,034 in 2025
The $1,034 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $527 · 2024: $1,257 · 2025: $1,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,817.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $423.93 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $245.95 | 2023-2025 | Gardasil 9, Capvaxive, Enflonsia |
| Amgen INC. | $233.27 | 2023-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $227.79 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $211.07 | 2023-2025 | |
| Glaxosmithkline, LLC. | $197.72 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Phathom Pharmaceuticals, INC. | $173.85 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $145.17 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $116.17 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.22 | 2024-2025 | Jardiance, Tradjenta |
| Eisai INC. | $78.50 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.97 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $71.63 | 2023-2024 | |
| Atricure, INC. | $63.24 | 2024 | |
| Esperion Therapeutics, INC. | $59.25 | 2023-2025 | Nexletol |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $58.39 | 2025 | |
| Aimmune Therapeutics, INC. | $54.11 | 2025 | Vowst |
| Xeris Pharmaceuticals, INC. | $44.61 | 2024 | Keveyis |
| Lundbeck LLC | $42.48 | 2023-2024 | Vyepti |
| Novo Nordisk INC | $37.62 | 2024-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $24.28 | 2024 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $24.16 | 2025 | Strensiq |
| Hologic Sales and Service, LLC | $23.90 | 2025 | Aptima |
| Watermark Medical, INC. | $19.34 | 2024 | |
| Daiichi Sankyo INC. | $18.66 | 2025 | Injectafer |
| Medtronic, INC. | $15.15 | 2024 | Intellis Adaptivestim |
| E.R. Squibb & Sons, L.L.C. | $13.44 | 2024 | Camzyos |
| Idorsia Pharmaceuticals US INC | $13.25 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Abbott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.